Chimeric Therapeutics aspires to be a leader in cell therapy and to develop life-changing medicines for humankind
-
We put patients first
-
We demonstrate compassion and kindness to our patients and their families
-
We strive to do the right thing
-
Our people are our greatest assets
-
We are intellectually curious
-
Our science is data driven
-
We are collaborative
-
We value relationships based on trust and integrity
-
We will be good stewards of our investors’ capital
-
We will admit our mistakes and seek to learn from them
-
We aim to have fun
-
The value of our output must be worth more than the inputs
Latest Media Releases
Latest News
Market Reports /
by Peter Milios -
A year ago
19 Jan 2023 - The Chief Economist at Betashares, David Bassanese, stated that modest decline in recorded employment during December shows signs of the slowdown in labour demand. Ho…
Market Reports /
by Peter Milios -
A year ago
19 Jan 2023 - Australia’s unemployment rate is unchanged from an upwardly revised 3.5 per cent in November. The news resulted in the S&P/ASX 200 reaching 0.24 per cent or 18 points…
Market Reports /
by Peter Milios -
A year ago
22 Dec 2022 - The ASX has rallied for a second straight day, closing 0.53 per cent or 37 points higher at 7,152.50.
Market Reports /
by Peter Milios -
A year ago
22 Dec 2022 - Overnight, US consumer confidence data for December revealed the highest level since April. As a result, at noon, the S&P/ASX 200 is 0.53 per cent or 37.69 points hig…
Market Reports /
by Peter Milios -
A year ago
21 Nov 2022 - In a relatively quiet session, Utilities have led the day, following big results from Mercury NZ (ASX:MCY), which closed 4.31 per cent higher, and AGL Energy (ASX:AGL…
Market Reports /
by Lauren Hayes -
A year ago
21 Nov 2022 - The Australian market is having a lacklustre start to the trading week after US equity markets posted gains on Friday on news of strong earnings reports, but ended lo…
Interviews /
by Lauren Hayes -
A year ago
04 Nov 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow discusses the company's new agreement with Case Western Reserve University.
Market Reports /
by Peter Milios -
A year ago
02 Nov 2022 - Commonwealth Bank of Australia (ASX:CBA) today announced that it will raise its home loan variable interest rate by 25 basis points, in line with the RBA’s Melbourne …
Market Reports /
by Lauren Hayes -
A year ago
02 Nov 2022 - US markets turned negative overnight following job openings in September, which showed a resilient labour market and made investors brace for another likely 75 basis …
Market Reports /
by Lauren Hayes -
A year ago
28 Oct 2022 - Disappointing earnings from major US tech companies, including Meta, Apple and Amazon, has caused the Information Technology sector on the ASX to fall by 2.17 per cen…
Market Reports /
by Melissa Darmawan -
A year ago
05 Jul 2022 - Australian shares held on to their gains after the Reserve Bank of Australia reaffirmed its pledge to keep tightening monetary policy, joining other global central ba…
Market Reports /
by Melissa Darmawan -
A year ago
09 Jun 2022 - The Australian sharemarket fell to a 4-week low pulled down by banks as concerns of rising interest rates and bad debts weighed on investor sentiment. Adding to the f…
Market Reports /
by Melissa Darmawan -
A year ago
09 Jun 2022 - The major banks weigh on the Australian sharemarket after the Reserve Bank of Australia announced its outsized interest rate hike this week. Investors are concerned a…
Interviews /
by Melissa Darmawan -
A year ago
18 May 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an update on clinical trial progression, and discusses recent agreements with…
Company Presentations /
by -
2 years ago
25 Feb 2022 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow provides an overview of the company, discussing the company's cell therapy portfolio, …
Interviews /
by Melissa Darmawan -
2 years ago
08 Feb 2022 - Chimeric Therapeutics (ASX:CHM) CEO and Managing Director Jennifer Chow provides an overview progress since the company's IPO and discusses next steps.
Interviews /
by Melissa Darmawan -
2 years ago
30 Nov 2021 - Chimeric Therapeutics Limited (ASX:CHM) CEO and Managing Director Jennifer Chow talks about the recent presentation of data from the CHM 1101 (Chlorotoxin CAR T) Phas…
Interviews /
by Melissa Darmawan -
2 years ago
26 Aug 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's licensing of a novel, third-generation CDH17 CAR T cell therap…
Interviews /
by Melissa Darmawan -
2 years ago
07 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow talks about the company's phase 1 trial results for its chlorotoxin CAR T (CLTX CAR T) c…
Company Presentations /
by -
2 years ago
03 Jun 2021 - Chimeric Therapeutics Limited (ASX:CHM) Chief Operating Officer Jennifer Chow presents on the company's chlorotoxin CAR T cell therapy for the treatment of glioblasto…
Market Reports /
by Melissa Darmawan -
3 years ago
22 Apr 2021 - The ASX closed 0.8% higher to end the session shy of its 14-month high. Citi has downgraded Pilbara minerals (ASX:PLS) as a sell while Credit Suisse has downgraded Ch…
Company News /
by Melissa Darmawan -
3 years ago
22 Apr 2021 - A snapshot of the top news for the hour featuring OZ Minerals, Chimeric Therapeutics, AGL Energy.
Market Reports /
by Anna Napoli -
3 years ago
18 Jan 2021 - Australia’s sharemarket closed lower today despite a strong performance from some of our retailers. The S&P/ASX 200 index finished 52 points down or 0.8 per cent lowe…